Cost-effectiveness of CT and PET-CT for determining the need for adjuvant neck dissection in locally advanced head and neck cancer

被引:50
作者
Sher, D. J. [1 ,3 ]
Tishler, R. B. [1 ]
Annino, D. [2 ]
Punglia, R. S. [1 ,3 ]
机构
[1] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Div Otolaryngol, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA
关键词
cost-effectiveness analysis; neck dissection; radiotheraphy; PET-CT; POSITRON-EMISSION-TOMOGRAPHY; PLUS CONCURRENT CISPLATIN; SQUAMOUS-CELL HEAD; QUALITY-OF-LIFE; PHASE-II TRIAL; RANDOMIZED-TRIAL; LUNG-CANCER; MANAGEMENT; RADIOTHERAPY; CHEMOTHERAPY;
D O I
10.1093/annonc/mdp405
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Patients with node-positive head and neck squamous cell carcinomas (HNC) have a significant risk of residual disease (RD) in the neck after treatment, despite optimal chemoradiotherapy (CRT). Adjuvant neck dissection (ND) after CRT has been considered standard treatment, but its morbidity has led investigators to consider using postCRT imaging to determine the need for surgery. We analyzed the cost-effectiveness of computed tomography (CT) and positron emission tomography-computed tomography (PET-CT) as predictors of the need for ND compared with ND for all patients. Materials and methods: We developed a Markov model to describe health states in the 5 years after CRT for HNC in a 50-year-old man. We compared three strategies: dissect all patients, dissect patients with RD on CT, and dissect patients with RD on PET-CT. Probabilistic sensitivity analyses were carried out to model uncertainty in PET-CT performance, up-front and salvage dissection costs, and patient utilities. Results: ND only for patients with RD on PET-CT was the dominant strategy over a wide range of realistic and exaggerated assumptions. Probabilistic sensitivity analyses confirmed that the PET-CT strategy was almost certainly cost-effective at a societal willingness-to-pay threshold of $ 500 000/ quality-adjusted life year. Conclusion: Adjuvant ND reserved for patients with RD on PET-CT is the dominant and cost-effective strategy. original article
引用
收藏
页码:1072 / 1077
页数:6
相关论文
共 33 条
[1]   Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: Radiation therapy oncology group phase II trial 99-14 [J].
Ang, KK ;
Harris, J ;
Garden, AS ;
Trotti, A ;
Jones, CU ;
Carrascosa, L ;
Cheng, JD ;
Spencer, SS ;
Forastiere, A ;
Weber, RS .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) :3008-3015
[2]   The effect of neck dissection on quality of life after chemoradiation [J].
Donatelli-Lassig, Amy Anne ;
Duffy, Sonia A. ;
Fowler, Karen E. ;
Ronis, David L. ;
Chepeha, Douglas B. ;
Terrell, Jeffrey E. .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2008, 139 (04) :511-518
[3]   Managed care, hospice use, site of death, and medical expenditures in the last year of life [J].
Emanuel, EJ ;
Ash, A ;
Yu, W ;
Gazelle, G ;
Levinsky, NG ;
Saynina, O ;
McClellan, M ;
Moskowitz, M .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (15) :1722-1728
[4]   Planned neck dissection after concomitant radiochemotherapy for advanced head and neck cancer [J].
Frank, DK ;
Hu, KS ;
Culliney, BE ;
Persky, MS ;
Nussbaum, M ;
Schantz, SP ;
Malamud, SC ;
Holliday, RA ;
Khorsandi, AS ;
Sessions, RB ;
Harrison, LB .
LARYNGOSCOPE, 2005, 115 (06) :1015-1020
[5]   Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: A Phase II trial of the Radiation Therapy Oncology Group (RTOG 99-14) [J].
Garden, Adam S. ;
Harris, Jonathan ;
Trotti, Andy ;
Jones, Christopher U. ;
Carrascosa, Luis ;
Cheng, Jonathan D. ;
Spencer, Sharon S. ;
Forastiere, Arlene ;
Weber, Randal S. ;
Ang, K. Kian .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 71 (05) :1351-1355
[6]   Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An intergroup trial of the eastern cooperative oncology group [J].
Gibson, MK ;
Li, Y ;
Murphy, B ;
Hussain, MHA ;
DeConti, RC ;
Ensley, J ;
Forastiere, AA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3562-3567
[7]  
HARPOLE DH, 1995, CANCER-AM CANCER SOC, V76, P787, DOI 10.1002/1097-0142(19950901)76:5<787::AID-CNCR2820760512>3.0.CO
[8]  
2-Q
[9]  
Hollenbeak CS, 2001, CANCER-AM CANCER SOC, V92, P2341, DOI 10.1002/1097-0142(20011101)92:9<2341::AID-CNCR1581>3.0.CO
[10]  
2-8